Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0154007. PLoS One. 2017 Apr 20;12 (4):e0176578.

2.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

3.

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.

Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR.

Eur J Cancer. 2016 Mar;56:69-76. doi: 10.1016/j.ejca.2015.12.012. Epub 2016 Jan 25.

PMID:
26820797
4.

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.

Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B, Wu J, Zhang S.

Tumour Biol. 2015 May;36(5):3301-8. doi: 10.1007/s13277-014-2961-2. Epub 2014 Dec 19.

PMID:
25524577
5.

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.

Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.

Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.

PMID:
28576749
6.

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.

Modest DP, Camaj P, Heinemann V, Schwarz B, Jung A, Laubender RP, Gamba S, Haertl C, Stintzing S, Primo S, Bruns CJ.

J Cancer Res Clin Oncol. 2013 Jun;139(6):953-61. doi: 10.1007/s00432-013-1401-9. Epub 2013 Mar 2.

PMID:
23455880
7.

A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.

Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H.

Oncotarget. 2016 Jul 12;7(28):44299-44309. doi: 10.18632/oncotarget.9996.

8.

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.

Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R.

FASEB J. 2015 Feb;29(2):464-76. doi: 10.1096/fj.14-262303. Epub 2014 Oct 30.

9.

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.

Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH, Chiao PJ.

Nat Commun. 2017 Feb 24;8:14437. doi: 10.1038/ncomms14437.

10.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

11.

Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.

Zhang W, Li H, Yang Y, Liao J, Yang GY.

Cancer Lett. 2014 Dec 28;355(2):273-80. doi: 10.1016/j.canlet.2014.09.031. Epub 2014 Oct 7.

12.

Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.

Bousquet MS, Ma JJ, Ratnayake R, Havre PA, Yao J, Dang NH, Paul VJ, Carney TJ, Dang LH, Luesch H.

ACS Chem Biol. 2016 May 20;11(5):1322-31. doi: 10.1021/acschembio.5b00860. Epub 2016 Mar 3.

13.

Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.

Kalimutho M, Bain AL, Mukherjee B, Nag P, Nanayakkara DM, Harten SK, Harris JL, Subramanian GN, Sinha D, Shirasawa S, Srihari S, Burma S, Khanna KK.

Mol Oncol. 2017 May;11(5):470-490. doi: 10.1002/1878-0261.12040. Epub 2017 Mar 27.

14.

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S.

Nat Commun. 2017 Feb 21;8:14294. doi: 10.1038/ncomms14294.

15.

Targeting mTOR dependency in pancreatic cancer.

Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ; Australian Pancreatic Cancer Genome Initiative (APGI), Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP.

Gut. 2014 Sep;63(9):1481-9. doi: 10.1136/gutjnl-2013-306202. Epub 2014 Apr 9.

16.

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.

Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.

Int J Cancer. 2013 Aug 15;133(4):984-96. doi: 10.1002/ijc.28073. Epub 2013 Mar 8.

17.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25.

18.

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.

Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M.

Nat Commun. 2016 May 19;7:11363. doi: 10.1038/ncomms11363.

19.

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3570-7. doi: 10.1200/JCO.2012.42.2592. Epub 2012 Jun 25.

PMID:
22734028
20.

Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.

Raja M, Zverev M, Seipel K, Williams GT, Clarke AR, Shaw PH.

Mol Cancer Ther. 2015 Oct;14(10):2175-86. doi: 10.1158/1535-7163.MCT-15-0223. Epub 2015 Jul 23.

Supplemental Content

Support Center